Tibotec Intelence Not For First-Line Use, FDA Says; Is Follow-On Naive?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The drug interaction profile of Johnson & Johnson subsidiary Tibotec’s antiretroviral Intelence (etravirine) precludes its first-line use against HIV, leaving open a therapeutic niche that Tibotec hopes to fill with another non-nucleoside reverse transcriptase inhibitor, TMC278.